KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Leases (2017 - 2025)

BeOne Medicines (ONC) has disclosed Leases for 9 consecutive years, with $148.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases rose 6.37% to $148.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $148.2 million, a 6.37% increase, with the full-year FY2025 number at $148.2 million, up 6.37% from a year prior.
  • Leases was $148.2 million for Q4 2025 at BeOne Medicines, up from $140.2 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $148.2 million in Q4 2025 to a low of $86.9 million in Q1 2021.
  • A 5-year average of $113.5 million and a median of $109.5 million in 2022 define the central range for Leases.
  • Peak YoY movement for Leases: dropped 19.49% in 2024, then soared 66.86% in 2025.
  • BeOne Medicines' Leases stood at $117.4 million in 2021, then dropped by 6.36% to $110.0 million in 2022, then decreased by 13.42% to $95.2 million in 2023, then skyrocketed by 46.32% to $139.3 million in 2024, then grew by 6.37% to $148.2 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Leases are $148.2 million (Q4 2025), $140.2 million (Q3 2025), and $145.8 million (Q2 2025).